Cite this post as:
Scott Weingart, MD FCCM. Bleeding Patients on Dabigatran aka Pradaxa. EMCrit Blog. Published on May 27, 2011. Accessed on December 11th 2023. Available at [https://emcrit.org/emcrit/bleeding-patients-on-dabigatran/ ].
Financial Disclosures:
Dr. Scott Weingart, Course Director, reports no relevant financial relationships with ineligible companies.
This episode’s speaker(s), (listed above), report no relevant financial relationships with ineligible companies.
CME Review
Original Release: May 27, 2011
Date of Most Recent Review: Jan 1, 2022
Termination Date: Jan 1, 2025
You finished the 'cast,
Now Join EMCrit!
As a member, you can...
- Get CME hours
- Get the On Deeper Reflection Podcast
- Support the show
- Write it off on your taxes or get reimbursed by your department
.
Get the EMCrit Newsletter
If you enjoyed this post, you will almost certainly enjoy our others. Subscribe to our email list to keep informed on all of the Resuscitation and Critical Care goodness.
This Post was by the EMCrit Crew, published 13 years ago. We never spam; we hate spammers! Spammers probably work for the Joint Commission.
hope all is well this early summer. Curious if the patient gets hemodialysis w/o heparin if the patient has a head bleed? TT time means the same as prothrombin time as an assay? factor 7 versus PCC, unknown which is better. I am not sure why the FDA would approve such a drug w/o a clear antidote. I guess the next product on market would be recombinant Thrombin to give to patients.
Jose,
great question. have not seen data, but i believe he the dabi itself should be enough anti-coag for the HD. When the filter clots, you are probably ready to stop the dialysis. TT is different than PT, unfortunately, so regular coags prob not the way to go. If it was my head I would want the Factor VIIa, b/c I really don’t see why PCC would do anything. As to FDA, you could argue that ther. dabi may still be a better deal than the frequent head bleeds we see with crazy INRs in pts on warfarin.
Hi,
Would you mind explaining your reasoning that Factor VIIa would be superior to PCC in this case?
My thoughts are (with the proviso, that i have no good evidence for any of this) that 3-factor PCC brings very little tot he table. None of these factors are in shortage with dabi and not sure how much thrombin for direct comptetition with dabi is going to be generated. 4-factor seems ok, b/c at least you have the VIIa, but why not just give the VIIa then in greater concentrations. This will get you the TF thrombin burst, which is probably where the money is. Also, putatively you are going to get direct plt activation with the VIIa preps.… Read more »
FEIBA should work, however
Scott,
Are you saying FEIBA should be better b/c it contains VIIa? And when you mention 4 factor PCC in the above comment isn’t that the same as FEIBA? Thanks for your help and clarification.
FEIBA is four factor with ACTIVATED factor VII; other 4-factor have inactive factor VII.
FEIBA also has activated II (thrombin), which is why (activated) PCC should work better than VIIa.
dabigatran inhibits thrombin (even if fibrin-bound), so even if you feed the coag system proximal to inhibited-thrombin, there should not be as much of an effect
not a lot of clinical data out there, though
(also, activated 3-factor pcc should work too)
VIIa has a signficant risk of thrombosis – even 4-factor PCC has a higher risk of thrombosis than 3-factor PCC.
James, do you have anything to support the thrombin content of FEIBA. I am doubtful there is any significant amount of thrombin in the product. If infusion of thrombin actually worked, we can dispense with the rest of the clotting cascade. Unfortunately, thrombosis rates really can’t be compared between studies–the selection and baseline clotting rates differ between each of the studies and makes it tough to really assess which products have increased relative rates.
As a relatively new patient taking this drug (3/11), this is important information to me. I just hope that if I do need to go into the ER with a bleed, they won’t be depending on me to figure it all out. O_o I have to say that I am not missing the monthly (or more frequent) trips to the cardiologist’s office for INR tests. And also dealing with my INR spikes and lows occurring without any changes in diet, and preparing for a procedure, although a pacer in Feb. has fixed what has been ailing me. If my next… Read more »
It has been a year and a half since I first read this website and listened to the video. Has anyone come up with any new strategies based on experience and experimentation? Thanks.
there are none. the company will self-release a very expensive antibody antidote.
They should not release drugs like this until they modify it so that it’s effects can be reversed or inactivated. How did these drugs get past the ethics committee?